Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from BriaCell Therapeutics ( (TSE:BCT) ).
BriaCell Therapeutics has announced the inclusion of UCLA Health Jonsson Comprehensive Cancer Center as a key site in its pivotal Phase 3 clinical study of Bria-IMT™ for advanced metastatic breast cancer. This collaboration is expected to enhance patient enrollment and accelerate trial execution, with interim analysis planned after 144 patient events. The study’s design builds on promising Phase 2 data and has received FDA Fast Track designation, highlighting its potential to address unmet medical needs in cancer treatment.
The most recent analyst rating on (TSE:BCT) stock is a Buy with a C$32.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
BriaCell Therapeutics has a challenging financial position with no revenue and consistent losses, heavily impacting its stock score. Despite this, recent corporate developments in cancer treatment provide some potential upside. Technical indicators are mixed, and valuation concerns persist with a negative P/E ratio. The company’s reliance on external financing is a notable risk.
To see Spark’s full report on TSE:BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care.
Average Trading Volume: 26,441
Technical Sentiment Signal: Sell
Current Market Cap: C$19.48M
Learn more about BCT stock on TipRanks’ Stock Analysis page.